Drug intelligence / Profile preview

CTH-800

Development stage: Preclinical
Lead developer: Cartherics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CTH-800 is a preclinical-stage therapeutic candidate being developed by Cartherics. It utilizes extracellular vesicles (EVs) as its primary modality. Extracellular vesicles are nano-sized, membrane-bound particles naturally secreted by cells that serve as vehicles for intercellular communication, carrying proteins, lipids, and nucleic acids. Cartherics is investigating CTH-800 for various undisclosed indications, aiming to leverage the inherent delivery and signaling properties of EVs for therapeutic benefit.

Beyond the preview

Go deeper on CTH-800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-800.

Explore the full profile